109 related articles for article (PubMed ID: 19025669)
1. Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.
Zhu ZF; Chen LJ; Lu R; Jia J; Liang Y; Xu Q; Zhou CL; Wang L; Wang S; Yao Z
BMC Cancer; 2008 Nov; 8():342. PubMed ID: 19025669
[TBL] [Abstract][Full Text] [Related]
2. Tyroserleutide tripeptide affects calcium homeostasis of human hepatocarcinoma BEL-7402 cells.
Fu Z; Lu R; Li G; Zhao L; Gao W; Che X; Jian X; Zhou C; Yao Z
Sci China C Life Sci; 2005 Oct; 48(5):523-30. PubMed ID: 16315604
[TBL] [Abstract][Full Text] [Related]
3. The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma.
Yao Z; Lu R; Jia J; Zhao P; Yang J; Zheng M; Lu J; Jin M; Yang H; Gao W
Peptides; 2006 Jun; 27(6):1167-72. PubMed ID: 16129512
[TBL] [Abstract][Full Text] [Related]
4. A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice.
Jia JB; Wang WQ; Sun HC; Liu L; Zhu XD; Kong LQ; Chai ZT; Zhang W; Zhang JB; Xu HX; Zeng ZC; Wu WZ; Wang L; Tang ZY
Invest New Drugs; 2011 Oct; 29(5):861-72. PubMed ID: 20414698
[TBL] [Abstract][Full Text] [Related]
5. Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma.
Zhao L; Zhao Q; Lu R; Fu Z; Zhu Z; Jia J; Wang S; Shi L; Jian X; Yao Z
J Cell Biochem; 2008 Feb; 103(2):471-8. PubMed ID: 17546603
[TBL] [Abstract][Full Text] [Related]
6. Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma.
Wang C; Wang S; Lu R; Zhao L; Zhu ZF; Xu Q; Lv JQ; Wang LL; Fu Z; Lin G; Yao Z
Anticancer Drugs; 2009 Aug; 20(7):534-42. PubMed ID: 19491661
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay.
Li XL; Liu JY; Lu R; Xu Q; Zhu ZF; Wang L; Zhou CL; Jia J; Fu Z; Yao Z
Invest New Drugs; 2008 Dec; 26(6):525-9. PubMed ID: 18264678
[TBL] [Abstract][Full Text] [Related]
8. Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL).
Lu R; Jia J; Bao L; Fu Z; Li G; Wang S; Wang Z; Jin M; Gao W; Yao Z
Cancer Chemother Pharmacol; 2006 Jan; 57(2):248-56. PubMed ID: 16028100
[TBL] [Abstract][Full Text] [Related]
9. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
[TBL] [Abstract][Full Text] [Related]
10. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
11. Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1beta, TNF-alpha, and NO in vitro.
Yao Z; Qiu S; Wang L; Lu R; Zhou CL; Zhao PP; Li HQ; Gao WY
Cancer Immunol Immunother; 2006 Jan; 55(1):56-60. PubMed ID: 16091933
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Bai XL; Zhang Q; Ye LY; Hu QD; Fu QH; Zhi X; Su W; Su RG; Ma T; Chen W; Xie SZ; Chen CL; Liang TB
Mol Cancer Ther; 2014 Aug; 13(8):2062-72. PubMed ID: 24867249
[TBL] [Abstract][Full Text] [Related]
14. Subcellular location of antitumor tripeptide-tyroserleutide in human hepatocellular carcinoma cells.
Jian X; Fu Z; Zhang Y; Che X; Lu R; Yao Z
Exp Ther Med; 2012 Feb; 3(2):195-199. PubMed ID: 22969868
[TBL] [Abstract][Full Text] [Related]
15. Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.
Yao Z; Che XC; Lu R; Zheng MN; Zhu ZF; Li JP; Jian X; Shi LX; Liu JY; Gao WY
Mol Med; 2007; 13(1-2):14-21. PubMed ID: 17515953
[TBL] [Abstract][Full Text] [Related]
16. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
17. [Study on the inhibitory effect of small tripeptide CMS024 on tumor growth and metastasis in nude mice model of human hepatocellular carcinoma metastasis].
Li Y; Tang ZY; Wang L; Yao Z; Lu R; Xue Q; Gao DM; Chen J
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(8):675-9. PubMed ID: 15130313
[TBL] [Abstract][Full Text] [Related]
18. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy.
Liang P; Wang M; Zhang S; Wang J; Dai C; Quan C
Adv Healthc Mater; 2019 Aug; 8(15):e1900306. PubMed ID: 31211520
[TBL] [Abstract][Full Text] [Related]
19. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the inhibitory effect of tripeptide tyroservatide on growth of human hepatocellular carcinoma using a hollow fiber assay].
Shi LX; Lu R; Wang L; Zhou CL; Xu Q; Zhu ZF; Ma R; Zhang HL; Jia J; Fu Z; Yao Z
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):725-8. PubMed ID: 19173797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
